FCM
MRNA icon

Fieldview Capital Management’s Moderna MRNA Stock Holding History

Fieldview Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,752
Closed -$1.73M – 645
2025
Q4 		$1.73M Buy
+58,752
New +$1.6M 0.29% 113
2025
Q3 		– Sell
-53,580
Closed -$1.48M – 485
2025
Q2 		$1.48M Buy
+53,580
New +$1.41M 0.22% 155

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fieldview Capital Management's MRNA Position: Q1 2026 in Review

Fieldview Capital Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 58,752 shares — an estimated $1.73M sold.

Fieldview Capital Management first reported a position in MRNA in Q2 2025 and held it in 2 quarters. The position peaked at $1.73M in Q4 2025. 726 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Fieldview Capital Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Fieldview Capital Management sold 58,752 Moderna shares in Q1 2026, an estimated $1.73M.
  • Fieldview Capital Management first reported a position in Moderna in Q2 2025 and held it in 2 quarters.
  • Fieldview Capital Management's Moderna position peaked at $1.73M in Q4 2025.
  • 726 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Fieldview Capital Management's 13F filing for Q1 2026, filed 14 May 2026.